Financials in USD. Standardized financial statements.
A compact view of how Infinity Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $2.59M | $1.86M | $1.72M | $3.05M |
| Revenue Growth? | +39.6% | +8.1% | -43.6% | 0.0% |
| Cost of Revenue? | $1.56M | $1.12M | $1.04M | $7.31M |
| Gross Profit? | $1.03M | $738,000 | $682,000 | -$4.26M |
| Gross Margin? | +39.7% | +39.7% | +39.7% | -139.7% |
| Operating Expenses? | $45.87M | $45.82M | $39.18M | $41.41M |
| Operating Income? | -$44.84M | -$45.08M | -$38.50M | -$45.66M |
| EBITDA? | -$43.73M | -$44.60M | -$37.56M | -$44.33M |
| Income Before Tax | -$44.37M | -$45.26M | -$40.49M | -$47.11M |
| Income Tax Expense | $0 | $0 | $0 | -$54,000 |
| Net Income? | -$44.37M | -$45.26M | -$40.49M | -$47.06M |
| EPS? | $-0.50 | $-0.53 | $-0.68 | $-0.83 |
| Diluted EPS? | $-0.50 | $-0.53 | $-0.68 | $-0.83 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality